ft819
Generic: iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819·Code: FT819
ft819: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| FATE THERAPEUTICS INC (FATE) | Phase 2 |
FDA Decisions
FDA_MeetingEngaged with FDA under RMAT to align on a registrational study design with the goal of initiating a pivotal study in 2026.(FATE)
Frequently asked questions
Who is developing ft819?
ft819 is being developed by FATE THERAPEUTICS INC.
What is ft819's latest FDA decision?
The most recent tracked FDA decision for ft819 is FDA_Meeting for Engaged with FDA under RMAT to align on a registrational study design with the goal of initiating a pivotal study in 2026..
Get deeper analysis on ft819
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis